Compare Hims and Hers Health Inc (HIMS) vs Oracle Corporation (ORCL) Price & Performance

HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.

The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.

Oracle Corporation (ORCL) is trading at $135.56, down 5.58% amid broader market volatility despite strong Q1 2026 earnings that beat expectations with EPS of $2.11 versus $1.96. The stock faces technical bearish signals with support at $133 and resistance at $141, while fundamentals show robust revenue growth to $57.4B in 2025 and net income margin expansion to 26.36%. Recent AI-driven infrastructure investments and layoffs highlight strategic shifts to capitalize on cloud demand.

Oracle's outlook remains positive with analyst consensus price target of $236.52 implying 74% upside, supported by 65% buy ratings. Key opportunities include AI cloud revenue growth accelerating 120% in Q1 2026, though risks persist from high debt levels ($85.3B long-term) and sensitivity to Fed policy given the stock's 1.9 beta. Investors should weigh strong profitability against execution risks in aggressive data center expansion.